Standard

Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019 : a randomized, controlled trial. / Huygens, Sammy; Hofsink, Quincy; Nijhof, Inger S et al.

In: The Journal of infectious diseases, Vol. 227, No. 2, 11.01.2023, p. 206-210.

Research output: Contribution to journal › Article › Academic › peer-review

Harvard

Huygens, S, Hofsink, Q, Nijhof, IS, Goorhuis, A, Kater, AP, Te Boekhorst, PA, Swaneveld, F, Novotný, VM, Bogers, S, Welkers, MR, Papageorgiou, G, Rijnders, BJ & Heijmans, J 2023, 'Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: a randomized, controlled trial', The Journal of infectious diseases, vol. 227, no. 2, pp. 206-210. https://doi.org/10.1093/infdis/jiac334

APA

Huygens, S., Hofsink, Q., Nijhof, I. S., Goorhuis, A., Kater, A. P., Te Boekhorst, P. A., Swaneveld, F., Novotný, V. M., Bogers, S., Welkers, M. R., Papageorgiou, G., Rijnders, B. J., & Heijmans, J. (2023). Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: a randomized, controlled trial. The Journal of infectious diseases, 227(2), 206-210. https://doi.org/10.1093/infdis/jiac334

Vancouver

Huygens S, Hofsink Q, Nijhof IS, Goorhuis A, Kater AP, Te Boekhorst PA et al. Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: a randomized, controlled trial. The Journal of infectious diseases. 2023 Jan 11;227(2):206-210. Epub 2022 Aug 4. doi: 10.1093/infdis/jiac334

Author

Huygens, Sammy ; Hofsink, Quincy ; Nijhof, Inger S et al. / Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019 : a randomized, controlled trial. In: The Journal of infectious diseases. 2023 ; Vol. 227, No. 2. pp. 206-210.

BibTeX

@article{8623ef57053546b3978bbb3150aea573,
title = "Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: a randomized, controlled trial",
abstract = "BACKGROUND: The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. METHODS: Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. RESULTS: Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher's exact test). CONCLUSIONS: Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available.",
keywords = "B-cell dysfunction, COVID-19, anti-SARS-CoV-2 hyperimmune globulin, plasma-derived antibody therapy, severely immunocompromised state",
author = "Sammy Huygens and Quincy Hofsink and Nijhof, {Inger S} and Abraham Goorhuis and Kater, {Arnon P} and {Te Boekhorst}, {Peter Aw} and Francis Swaneveld and Novotn{\'y}, {V{\v e}ra Mj} and Susanne Bogers and Welkers, {Matthijs Ra} and Grigorios Papageorgiou and Rijnders, {Bart J} and Jarom Heijmans",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.",
year = "2023",
month = jan,
day = "11",
doi = "10.1093/infdis/jiac334",
language = "English",
volume = "227",
pages = "206--210",
journal = "Journal of infectious diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

RIS

TY - JOUR

T1 - Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019

T2 - a randomized, controlled trial

AU - Huygens, Sammy

AU - Hofsink, Quincy

AU - Nijhof, Inger S

AU - Goorhuis, Abraham

AU - Kater, Arnon P

AU - Te Boekhorst, Peter Aw

AU - Swaneveld, Francis

AU - Novotný, Věra Mj

AU - Bogers, Susanne

AU - Welkers, Matthijs Ra

AU - Papageorgiou, Grigorios

AU - Rijnders, Bart J

AU - Heijmans, Jarom

N1 - Publisher Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

PY - 2023/1/11

Y1 - 2023/1/11

N2 - BACKGROUND: The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. METHODS: Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. RESULTS: Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher's exact test). CONCLUSIONS: Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available.

AB - BACKGROUND: The aim of this randomized, controlled trial is to determine whether antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin (COVIG) protects against severe coronavirus disease 2019 (COVID-19) in severely immunocompromised, hospitalized, COVID-19 patients. METHODS: Patients were randomly assigned to receive COVIG or intravenous immunoglobulin (IVIG) without SARS-CoV-2 antibodies. RESULTS: Severe COVID-19 was observed in 2 of 10 (20%) patients treated with COVIG compared to 7 of 8 (88%) in the IVIG control group (P = .015, Fisher's exact test). CONCLUSIONS: Antisevere acute respiratory syndrome coronavirus 2 hyperimmune globulin may be a valuable treatment in severely immunocompromised, hospitalized, COVID-19 patients and should be considered when no monoclonal antibody therapies are available.

KW - B-cell dysfunction

KW - COVID-19

KW - anti-SARS-CoV-2 hyperimmune globulin

KW - plasma-derived antibody therapy

KW - severely immunocompromised state

UR - http://www.scopus.com/inward/record.url?scp=85138789408&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiac334

DO - 10.1093/infdis/jiac334

M3 - Article

C2 - 35921542

VL - 227

SP - 206

EP - 210

JO - Journal of infectious diseases

JF - Journal of infectious diseases

SN - 0022-1899

IS - 2

ER -

ID: 28042012